KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Prepaid Assets (2017 - 2025)

Historic Prepaid Assets for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.9 million.

  • Aquestive Therapeutics' Prepaid Assets rose 4832.66% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 4832.66%. This contributed to the annual value of $3.3 million for FY2024, which is 7723.84% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Prepaid Assets of $2.9 million as of Q3 2025, which was up 4832.66% from $1.2 million recorded in Q2 2025.
  • Aquestive Therapeutics' Prepaid Assets' 5-year high stood at $3.9 million during Q1 2021, with a 5-year trough of $1.2 million in Q2 2024.
  • In the last 5 years, Aquestive Therapeutics' Prepaid Assets had a median value of $2.1 million in 2024 and averaged $2.3 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first tumbled by 3104.69% in 2023, then skyrocketed by 7723.84% in 2024.
  • Aquestive Therapeutics' Prepaid Assets (Quarter) stood at $3.1 million in 2021, then plummeted by 30.74% to $2.1 million in 2022, then fell by 13.0% to $1.9 million in 2023, then surged by 77.24% to $3.3 million in 2024, then fell by 10.99% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $1.2 million for Q2 2025, and $2.9 million during Q1 2025.